Nothing noteworthy (new) as it pertains to MNTA or HALO on the call. MNTA just got a passing mention and HyQ just repeated submission/expectation info from prior calls.
They did mention that their Alzheimer's Gammagard study has a futility analysis this quarter (120 patients 18 month treatment). If there is no stop then they will start enrolling a second (confirmatory) trial. The first trial is scheduled to end this year with data early next (if its not stopped early).
Market Data 
Markets 
AI
